ACHIEVE LIFE SCIENCES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.63 USD | +1.98% |
|
+1.31% | +12.38% |
| Apr. 17 | JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target | MT |
| Mar. 28 | Transcript : Achieve Life Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Presenter SpeechJohn Bencich (Executives)Good afternoon. My name is John Bencich, and I am the...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Companyâs product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
Calendar
2024-05-01
- Planet MicroCap Showcase
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.54
USD
Average target price
19.75
USD
Spread / Average Target
+335.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.38% | 156M | |
| +0.51% | 43.84B | |
| +5.46% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.39% | 25.53B | |
| -24.49% | 18.18B | |
| -3.64% | 12.29B | |
| +25.85% | 12.29B | |
| +6.64% | 11.15B |
- Stock Market
- Equities
- ACHV Stock
- News Achieve Life Sciences, Inc.
- Transcript : Achieve Life Sciences, Inc. - Shareholder/Analyst Call
